BRPI0606923A2 - substáncia para uso como um medicamento, uso de uma substáncia, método de manufatura de uma substáncia para uso como um medicamento, formulação farmacêutica, e, método de manufatura de uma formulação farmacêutica - Google Patents
substáncia para uso como um medicamento, uso de uma substáncia, método de manufatura de uma substáncia para uso como um medicamento, formulação farmacêutica, e, método de manufatura de uma formulação farmacêuticaInfo
- Publication number
- BRPI0606923A2 BRPI0606923A2 BRPI0606923-1A BRPI0606923A BRPI0606923A2 BR PI0606923 A2 BRPI0606923 A2 BR PI0606923A2 BR PI0606923 A BRPI0606923 A BR PI0606923A BR PI0606923 A2 BRPI0606923 A2 BR PI0606923A2
- Authority
- BR
- Brazil
- Prior art keywords
- substance
- pharmaceutical formulation
- manufacturing
- drug
- metal
- Prior art date
Links
- 239000000126 substance Substances 0.000 title abstract 9
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title 2
- 239000002184 metal Substances 0.000 abstract 4
- 150000001450 anions Chemical class 0.000 abstract 2
- 229940126601 medicinal product Drugs 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 150000002736 metal compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/02—Magnesium compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Iron (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SUBSTáNCIA PARA USO COMO UM MEDICAMENTO, USO DE UMA SUBSTáNCIA, MéTODO DE MANUFATURA DE UMA SUBSTáNCIA PARA USO COMO UM MEDICAMENTO, FORMULAçãO FARMACêUTICA, E, MéTODO DE MANUFATURA DE UMA FORMULAçãO FARMACêUTICA. Uma substância para uso como um medicamento, compreende um composto de metal misturado sólido de fórmula (I): M^ II^~ 1-a~M^ III^~ a~O~ b~A^ n-^ ~ c~zH~ 2~O (1) onde M^ II^ é pelo menos um metal bivalente; M^ III^ é pelo me nos um metal trivalente; A^ n-^ é pelo menos um ânion n-valente; 2 + a = 2b + <sym>cn < 0,9a. A substância pode ser produzida pelo aquecimento em uma temperatura de 200°C a 600°C, preferivelmente de 250°C a 500°C de uma substância que compreende um composto de fórmula (II): M^ II^~ 1-X~M^ III^~ X~(OH)~ 2~A^ n-^~ y~mH~ 2~O (II) onde M^ II^ é pelo menos um metal bivalente; M^ III^ é pelo menos um metal trivalente; A~ n-~ é pelo menos um ânion n-valente; x = <sym>yn O <x <243> 0,5, O <y <243> 1 e 0 < m <243> 10.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0502787.5A GB0502787D0 (en) | 2005-02-10 | 2005-02-10 | Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use |
| GB0502787.5 | 2005-02-10 | ||
| PCT/GB2006/000452 WO2006085079A2 (en) | 2005-02-10 | 2006-02-09 | Pharmaceutically active phosphate binders, their manufacture, compositions containing them and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0606923A2 true BRPI0606923A2 (pt) | 2009-12-01 |
| BRPI0606923B1 BRPI0606923B1 (pt) | 2019-06-18 |
Family
ID=34356109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0606923-1A BRPI0606923B1 (pt) | 2005-02-10 | 2006-02-09 | Substância para uso como um medicamento, uso de uma substância, método de manufatura de uma substância para uso como um medicamento, formulação farmacêutica, e, método de manufatura de uma formulação farmacêutica |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20080206358A1 (pt) |
| EP (2) | EP3120855A1 (pt) |
| JP (2) | JP5328157B2 (pt) |
| KR (3) | KR20070082918A (pt) |
| CN (2) | CN105412150B (pt) |
| AR (2) | AR053678A1 (pt) |
| AU (1) | AU2006213922B2 (pt) |
| BR (1) | BRPI0606923B1 (pt) |
| CA (1) | CA2597124C (pt) |
| ES (1) | ES2599152T3 (pt) |
| GB (1) | GB0502787D0 (pt) |
| IL (1) | IL184448A (pt) |
| MX (1) | MX2007009688A (pt) |
| MY (1) | MY150070A (pt) |
| NO (2) | NO341846B1 (pt) |
| NZ (1) | NZ556600A (pt) |
| RU (1) | RU2420297C2 (pt) |
| TW (1) | TWI461201B (pt) |
| WO (1) | WO2006085079A2 (pt) |
| ZA (1) | ZA200706160B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
| MY157620A (en) * | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
| GB0714670D0 (en) | 2007-07-27 | 2007-09-05 | Ineos Healthcare Ltd | Use |
| GB0720220D0 (en) * | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
| GB0913525D0 (en) | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
| GB201001779D0 (en) * | 2010-02-04 | 2010-03-24 | Ineos Healthcare Ltd | Composition |
| GB201005931D0 (en) | 2010-04-09 | 2010-05-26 | Isis Innovation | Immune modulation |
| US9649335B1 (en) * | 2016-03-30 | 2017-05-16 | Baylor University | Intravenous administration of an oxygen-enabled fluid |
| KR102036549B1 (ko) | 2018-10-08 | 2019-10-25 | (주)씨앤팜 | 활성성분을 포함하는 변성 다중층 수산화물 구조체를 포함하는 금속 수산화물 복합체 및 이의 제조 방법 |
| WO2020084349A1 (en) | 2018-10-25 | 2020-04-30 | Opko Ireland Global Holdings, Ltd | Methods of treatment with mixed metal compounds |
| EP4228611A4 (en) * | 2020-10-17 | 2024-11-06 | Mingowood Pharmacal, LLC | FORMULATION AND NON-COVALENT STABILIZATION OF OLIVETOLIC ACID DERIVATIVES |
| RU2758671C1 (ru) * | 2020-12-08 | 2021-11-01 | Федеральное государственное бюджетное учреждение науки Институт физики прочности и материаловедения Сибирского отделения Российской академии наук (ИФПМ СО РАН) | СПОСОБ ПОЛУЧЕНИЯ НАНОСТРУКТУРНЫХ ДВОЙНЫХ ГИДРОКСИДОВ НА ОСНОВЕ АЛЮМИНИЯ И ЩЕЛОЧНОЗЕМЕЛЬНЫХ МЕТАЛЛОВ, ТАКИХ КАК МАГНИЙ ИЛИ КАЛЬЦИЙ, ОБЛАДАЮЩИХ СВОЙСТВОМ ПОВЫШАТЬ pH КЛЕТОЧНОЙ СРЕДЫ, И НАНОСТРУКТУРЫ, ПОЛУЧЕННЫЕ ДАННЫМ СПОСОБОМ |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2838930C2 (de) * | 1978-09-07 | 1980-07-03 | Chemische Werke Huels Ag, 4370 Marl | Wäßriges Behandlungsmittel für Holz und Holzwerkstoffe und dessen Verwendung |
| US4514389A (en) * | 1981-05-06 | 1985-04-30 | Kyowa Chemical Industry Co. Ltd. | Gastric antacid and method for controlling pH of gastric juice |
| JPS606619A (ja) * | 1983-06-27 | 1985-01-14 | Kyowa Chem Ind Co Ltd | 鉄分欠乏症処置剤及びその製法 |
| US4566986A (en) * | 1984-08-31 | 1986-01-28 | Waldmann John J | Flocculating agents and processes for making them |
| US5153156A (en) * | 1989-04-18 | 1992-10-06 | Aristech Chemical Corporation | Process for making efficient anionic clay catalyst, catalysts made thereby, and method of making isophorone |
| US5246899A (en) * | 1991-08-16 | 1993-09-21 | Amoco Corporation | Simplified preparation of hydrotalcite-type clays |
| NL9201907A (nl) * | 1992-11-02 | 1994-06-01 | Tno | Peristaltisch mengende reactor en peristaltische kleppenpomp. |
| US5506248A (en) * | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
| GB9506126D0 (en) * | 1995-03-25 | 1995-05-10 | Johnson Matthey Plc | Pharmaceutical composition and method |
| GB9720061D0 (en) * | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
| US6720005B1 (en) * | 2000-07-07 | 2004-04-13 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Coated, platform-generating tablet |
| WO2003003809A2 (en) * | 2001-07-05 | 2003-01-16 | Marantech Holding, Llc | Methods of using electron active compounds for managing conditions afflicting mammals |
| RU2224713C2 (ru) * | 2001-11-28 | 2004-02-27 | Институт неорганической химии им. А.В.Николаева СО РАН (статус государственного учреждения) | Способ получения нанокомпозитных материалов |
| US20040161474A1 (en) * | 2002-05-24 | 2004-08-19 | Moerck Rudi E. | Rare earth metal compounds methods of making, and methods of using the same |
| JP4348426B2 (ja) * | 2002-08-29 | 2009-10-21 | 独立行政法人産業技術総合研究所 | 高選択性脱リン剤及びその製造方法 |
| US7381428B2 (en) * | 2003-08-26 | 2008-06-03 | Shire International Licensing B.V. | Stabilized lanthanum carbonate compositions |
| WO2005027876A1 (en) * | 2003-08-28 | 2005-03-31 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of benzimidazole and processes for their preparation |
| MY157620A (en) * | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
-
2005
- 2005-02-10 GB GBGB0502787.5A patent/GB0502787D0/en not_active Ceased
-
2006
- 2006-02-06 US US11/815,845 patent/US20080206358A1/en not_active Abandoned
- 2006-02-09 BR BRPI0606923-1A patent/BRPI0606923B1/pt not_active IP Right Cessation
- 2006-02-09 CN CN201510713549.XA patent/CN105412150B/zh not_active Expired - Fee Related
- 2006-02-09 WO PCT/GB2006/000452 patent/WO2006085079A2/en not_active Ceased
- 2006-02-09 JP JP2007554635A patent/JP5328157B2/ja not_active Expired - Fee Related
- 2006-02-09 KR KR1020077017214A patent/KR20070082918A/ko not_active Abandoned
- 2006-02-09 TW TW095104355A patent/TWI461201B/zh not_active IP Right Cessation
- 2006-02-09 CN CN200680004634.8A patent/CN101115490B/zh not_active Expired - Fee Related
- 2006-02-09 AU AU2006213922A patent/AU2006213922B2/en not_active Ceased
- 2006-02-09 KR KR1020137024757A patent/KR101491531B1/ko not_active Expired - Fee Related
- 2006-02-09 EP EP16174070.9A patent/EP3120855A1/en not_active Withdrawn
- 2006-02-09 MY MYPI20060564A patent/MY150070A/en unknown
- 2006-02-09 CA CA2597124A patent/CA2597124C/en not_active Expired - Fee Related
- 2006-02-09 ES ES06709690.9T patent/ES2599152T3/es not_active Expired - Lifetime
- 2006-02-09 KR KR1020147009809A patent/KR20140066756A/ko not_active Ceased
- 2006-02-09 RU RU2007133720/15A patent/RU2420297C2/ru not_active IP Right Cessation
- 2006-02-09 ZA ZA200706160A patent/ZA200706160B/xx unknown
- 2006-02-09 NZ NZ556600A patent/NZ556600A/en not_active IP Right Cessation
- 2006-02-09 EP EP06709690.9A patent/EP1850859B1/en not_active Expired - Lifetime
- 2006-02-09 MX MX2007009688A patent/MX2007009688A/es active IP Right Grant
- 2006-02-10 AR ARP060100490A patent/AR053678A1/es not_active Application Discontinuation
-
2007
- 2007-07-05 IL IL184448A patent/IL184448A/en not_active IP Right Cessation
- 2007-09-05 NO NO20074504A patent/NO341846B1/no not_active IP Right Cessation
-
2011
- 2011-10-11 US US13/270,358 patent/US20120093943A1/en not_active Abandoned
-
2013
- 2013-05-20 JP JP2013106271A patent/JP2013209401A/ja active Pending
-
2016
- 2016-11-15 AR ARP160103488A patent/AR106699A2/es unknown
-
2017
- 2017-11-08 NO NO20171769A patent/NO20171769A1/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0408347B8 (pt) | derivados de pirimidina, seu uso, e composição e combinação farmacêuticas | |
| UY30472A1 (es) | Nuevos derivados de pirimidina, procesos para su preparacion composiciones farmacéuticas conteniédolos, procesos para su preparacion y aplicaciones. | |
| MX2009011997A (es) | Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos. | |
| MY137039A (en) | Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof | |
| BRPI0409198A (pt) | derivados quinolin-2-ona para o tratamento de doenças de vias aéreas | |
| NO20070176L (no) | Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav | |
| NO20091893L (no) | Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav. | |
| SG155961A1 (en) | Pyrazoles as 11-beta-hsd-1 | |
| BRPI0410760A (pt) | compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos | |
| PE20050255A1 (es) | Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos | |
| NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
| BRPI0606923A2 (pt) | substáncia para uso como um medicamento, uso de uma substáncia, método de manufatura de uma substáncia para uso como um medicamento, formulação farmacêutica, e, método de manufatura de uma formulação farmacêutica | |
| BR112015019590A2 (pt) | derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv | |
| TW200732323A (en) | Organic compounds | |
| ATE484504T1 (de) | Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika | |
| UY28271A1 (es) | Compuestos químicos | |
| UY28366A1 (es) | Compuestos químicos | |
| UY30363A1 (es) | Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones | |
| MX2008009705A (es) | Composiciones farmaceuticas que contienen docetaxel, un inhibidor de degradacion y un proceso para obtener el mismo. | |
| UY28861A1 (es) | Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias | |
| DK1594885T3 (da) | Lægemiddel til vækstinhibering af tumorer | |
| CO5560555A2 (es) | Cristales de derivado de hidroxinorefedrina | |
| JO2734B1 (en) | Organic compounds | |
| AR029795A1 (es) | Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos | |
| ECSP099080A (es) | Combinaciones farmacológicas para el tratamiento de enfermedades de las vías aéreas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO MEMO/INPI/PROC/NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO. |
|
| B25A | Requested transfer of rights approved |
Owner name: CYTOCHROMA DEVELOPMENT INC. (BB) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2617 DE 02-03-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |